Targeting M1 muscarinic and sigma-1 receptors in Alzheimer’s disease: Reversal of pathological hallmarks and associated cognitive dysfunction in McGill-R-Thy1-APP rats
Anavex Life Sciences to Present at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases AD/PD™ 2017
Anavex Life Sciences’ CEO Joins BIO CEO & Investor Conference 2017 Panel “Designing Clinical Trials in 21st Century Cures Paradigm”
